- Home
- LEA vs RYTM Comparison
LEA vs RYTM Comparison
Compare LEA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEA
- RYTM
- Stock Information
- Founded
- LEA 1917
- RYTM 2008
- Country
- LEA United States
- RYTM United States
- Employees
- LEA N/A
- RYTM N/A
- Industry
- LEA Auto Parts:O.E.M.
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- LEA Consumer Discretionary
- RYTM Health Care
- Exchange
- LEA Nasdaq
- RYTM Nasdaq
- Market Cap
- LEA 5.4B
- RYTM 6.4B
- IPO Year
- LEA N/A
- RYTM 2017
- Fundamental
- Price
- LEA $104.21
- RYTM $102.49
- Analyst Decision
- LEA Buy
- RYTM Strong Buy
- Analyst Count
- LEA 11
- RYTM 12
- Target Price
- LEA $116.45
- RYTM $117.00
- AVG Volume (30 Days)
- LEA 674.4K
- RYTM 712.7K
- Earning Date
- LEA 10-31-2025
- RYTM 11-04-2025
- Dividend Yield
- LEA 2.96%
- RYTM N/A
- EPS Growth
- LEA N/A
- RYTM N/A
- EPS
- LEA 8.17
- RYTM N/A
- Revenue
- LEA $22,985,100,000.00
- RYTM $174,334,000.00
- Revenue This Year
- LEA N/A
- RYTM $46.10
- Revenue Next Year
- LEA $2.03
- RYTM $63.02
- P/E Ratio
- LEA $12.75
- RYTM N/A
- Revenue Growth
- LEA N/A
- RYTM 54.92
- 52 Week Low
- LEA $73.85
- RYTM $45.91
- 52 Week High
- LEA $113.10
- RYTM $116.00
- Technical
- Relative Strength Index (RSI)
- LEA 49.59
- RYTM 49.37
- Support Level
- LEA $99.00
- RYTM $99.44
- Resistance Level
- LEA $104.69
- RYTM $108.99
- Average True Range (ATR)
- LEA 2.91
- RYTM 5.24
- MACD
- LEA -0.77
- RYTM -0.15
- Stochastic Oscillator
- LEA 43.41
- RYTM 41.23
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.